secwatch.observer — SEC 8-K summary
======================================

Issuer:     Enliven Therapeutics, Inc. (ELVN)
CIK:        0001672619
Form:       8-K
Filed at:   2023-08-10T23:59:59+00:00
Accession:  0000950170-23-041322
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Enliven Therapeutics Q2 2023 net loss $16.7M; cash $277.9M; Phase 1 data expected 2024
--------------------------------------------------------------------------------

- Net loss of $16.7M for Q2 2023, compared to $8.9M in Q2 2022.
- Cash, cash equivalents and marketable securities total $277.9M as of June 30, 2023.
- R&D expenses $15.2M vs $7.9M; G&A expenses $5.0M vs $1.1M (year-over-year).
- Phase 1 trials for ELVN-001 (CML) and ELVN-002 (HER2+) advancing with initial safety/efficacy data expected in 2024.
- Third program product candidate selected; more details to be disclosed in 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1672619/000095017023041322/0000950170-23-041322-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1672619/000095017023041322/elvn-20230810.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-041322

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer